You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 General characteristics of the study patients

From: Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study

  Entire Cohort Propensity Score Matching
Characteristic   PORT (N = 58) POCRT (N = 33) P PORT (N = 33) POCRT (N = 33) P
Age (years) Mean 50 ± 15 51 ± 12 .793 48 ± 15 51 ± 12 .372
Sex Female/Male 37 (64)/21 (36) 17 (52)/16 (49) .275 18 (55)/15 (46) 17 (52)/16 (49) 1.000
Tumor subsite Parotid 16 (28) 6 (18) .394 7 (21) 6 (18) .692a
Submandibular 16 (28) 8 (24)   11 (33) 8 (24)  
Sublingual 8 (14) 3 (9)   4 (12) 3 (9)  
Minor salivary 18 (31) 16 (49)   11 (33) 16 (49)  
Performance score 0-1/2 57 (98)/1 (2) 30 (91)/3 (9) .134a 33 (100)/0 (0) 30 (91)/3 (9) .238a
T stage T1 23 (40) 5 (15) .099 12 (36) 5 (15) .137a
T2 15 (26) 10 (30)   9 (27) 10 (30)  
T3 5 (9) 5 (15)   1 (3) 5 (15)  
T4 15 (26) 13 (39)   11 (33) 13 (39)  
Tumor size (cm) Mean 2.4 ± 1.3 3.1 ± 1.7 .051 2.4 ± 1.3 3.1 ± 1.7 .060
N stage N0 52 (90) 26 (79) .332a 31 (94) 26 (79) .228a
N1 3 (5) 3 (9)   1 (3) 3 (9)  
N2 3 (5) 4 (12)   1 (3) 4 (12)  
Disease stage I 21 (36) 4 (12) .103 11 (33) 4 (12) .200a
II 14 (24) 10 (30)   8 (24) 10 (30)  
III 6 (10) 5 (15)   2 (6) 5 (15)  
IV 17 (29) 14 (42)   12 (36) 14 (42)  
MRI   17 (29) 17 (52) .044 10 (30) 17 (52) .132
18F-FDG-PET   15 (26) 16 (49) .039 15 (46) 16 (49) 1.000
Surgical margins <1 mm/≥1 mm 38 (66)/20 (35) 28 (85)/5 (15) .032 26 (79)/7 (21) 28 (85)/5 (15) .751
Histological features Perineural invasion 38 (66) 27 (82) .147 24 (73) 27 (82) .558
Nodal ECS 1 (2) 5 (15) .022a 0 (0) 5 (15) .053a
Bone invasion 9 (16) 11 (33) .066 8 (24) 11 (33) .587
Skin invasion 2 (3) 0 (0) .533a 1 (3) 0 (0) 1.000a
Muscle invasion 19 (33) 7 (21) .335 11 (33) 7 (21) .408
Lymphatic invasion 5 (9) 4 (12) .718a 1 (3) 4 (12) .355a
Vascular invasion 2 (3) 3 (9) .349a 2 (6) 3 (9) 1.000a
RT technique 3D-CRT 30 (52) 3 (9) < .001 8 (24) 3 (9) .340
IMRT 19 (33) 20 (61)   17 (52) 20 (61)  
VMAT 9 (16) 10 (30)   8 (24) 10 (30)  
RT dose >66 Gy 13 (22) 6 (18) .678a 5 (15) 6 (18) .810a
60–66 Gy 41 (71) 26 (79)   25 (76) 26 (79)  
<60 Gy 4 (7) 1 (3)   3 (9) 1 (3)  
RT period 2010–2013 13 (22) 12 (36) .001 11 (33) 12 (36) .556
2005–2009 15 (26) 17 (52)   11 (33) 17 (52)  
2000–2004 30 (52) 4 (12)   11 (33) 4 (12)  
Neck treatment Elective 27 (47) 15 (46) .677 13 (39) 15 (46) .411
Therapeutic 8 (14) 7 (21)   4 (12) 7 (21)  
None 23 (40) 11 (33)   16 (49) 11 (33)  
Treatment time Surgery to RT (days) 31 ± 12 37 ± 11 .018 35 ± 11 37 ± 11 .544
RT duration (days) 47 ± 9 48 ± 4 .770 46 ± 6 48 ± 4 .189
  1. Numbers in parentheses indicate percentages. Abbreviations: RT radiotherapy, PORT postoperative radiotherapy, POCRT postoperative chemoradiotherapy, MRI magnetic resonance imaging, 18 F-FDG PET 18F-Fluorodeoxyglucose positron emission tomography, ECS extracapsular spread, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, VMAT RapidArc volumetric-modulated arc therapy. aFisher’s exact test